V2 receptor Inhibitors
4 drugsAbout V2 receptor
The V2 receptor (AVPR2) is a G protein-coupled receptor that regulates water reabsorption in the kidneys, maintaining fluid balance. Activation of this receptor by vasopressin increases water permeability in kidney tubules. It plays a crucial role in concentrating urine and preventing dehydration.
Human genetics strongly support AVPR2 as a therapeutic target, with a max score of 0.87 linking loss-of-function variants to nephrogenic diabetes insipidus. Additional genetic associations include nephrogenic syndrome of inappropriate antidiuresis (0.85) and other genetic disorders (0.61). Activation of AVPR2 is likely beneficial based on genetic evidence.
Four FDA-approved small molecule drugs target AVPR2, including DDAVP (desmopressin) and various formulations of vasopressin. These drugs, developed by companies like NORDIC PHARMA, Dr. Reddy's, Baxter and GLAND, are used to treat rare diseases and other conditions related to fluid balance.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Hemorrhage with only 1 trials.
V2 receptor Genetic Evidence Strong
Strong genetic evidence supports AVPR2's role in nephrogenic diabetes insipidus (0.87) and related disorders.
Strong genetic support suggests that clinical trials targeting AVPR2 have a higher likelihood of success.
💡 Why activation?
- • Loss-of-function variants increase disease risk (OR > 1) — restoring function may help
- • 100% directional consistency across 2 traits
- • Strong signal in urinary system disease, genetic, familial or congenital disease pathways
Cross-Disease Effects
Trade-off: LowDirection of Effect
100% alignedEvidence Across Diseases
5 totalGWAS and other genetic studies link AVPR2 to 5 diseases.
Loss-of-function causes disease; activation may help
Loss-of-function causes disease; activation may help
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top V2 receptor Drugs
Four companies, including NORDIC PHARMA and Dr. Reddy's, have approved drugs targeting AVPR2.
The presence of established players suggests moderate barriers to entry in this market.
| Drug | Company | Approved | Indications |
|---|---|---|---|
| VASOPRESSIN IN SODIUM CHLORIDE 0.9% | Baxter | 2023 | 2 |
V2 receptor Drug Modality Landscape
Modalities
Routes of Administration
V2 receptor is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or peptides could provide a competitive advantage.
V2 receptor Clinical Trials 172 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 19 | 13 | 3 | 3 | 81% |
| Phase 2 | 51 | 30 | 13 | 8 | 70% |
| Phase 3 | 40 | 23 | 4 | 13 | 85% |
| Phase 4 | 62 | 36 | 10 | 14 | 78% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
V2 receptor Drug Approval Timeline (1978 - 2024)
The first drug was approved in 1978, with the most recent approval in 2024, spanning 47 years.
The continued approval of new drugs indicates sustained interest and potential for further innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 4 companies competing
- • Market share by company
Full Drug Portfolio
- • All 4 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 4-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 138 clinical trials targeting V2 receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities